DeutschNewstral
Article
Bbarrons.com on 2021-02-16 15:14
Bluebird Bio Suspends Gene Therapy Trials, Marketing After Cancer Diagnosis
Related news
- BGene-Therapy Firm Bluebird Bio Is Spinning Off Its Cancer Programsbarrons.com
- BBluebird Bio's Gene Therapy Is $1.8 Million Per Patient. The Stock Is Falling.barrons.com
- BWall Street Looks Again at Bluebird, Rivals, After Gene-Therapy Setbackbarrons.com
- BHow a Cloud Is Lifting from Bluebird and Other Gene Therapy Stocksbarrons.com
- BBluebird Says Gene-Therapy Patient's Cancer Seems Not Treatment-Relatedbarrons.com
- BBluebird Bio Stock Is Dropping. A Trial Was Halted for Safety.3 min readbarrons.com
- BBluebird Bio Gains on Analyst's Buy Callbarrons.com
- FBluebird Bio prices gene therapy at nearly $1.8mft.com
Cambridge gene therapy firm bluebird bio to move to Somervillebizjournals.com- Spark Therapeutics sues gene therapy rival Bluebird Biobizjournals.com
- Bluebird bio sued by gene therapy rival Spark Therapeuticsbizjournals.com
- Gene therapy developer bluebird bio to cut 30% of staffbizjournals.com
- Gene therapy firm bluebird bio to split into two companiesbizjournals.com
- Bluebird prices gene therapy in Europe at $1.8M over 5 yearsbizjournals.com
Building Europe’s gene therapy ecosystemPolitico.eu- BBluebird Bio Gains on Promising Cancer-Drug Databarrons.com
Bluebird Bio to Spin Off Cancer-Drug Unitwsj.com- Chicago biotech sues Third Rock, bluebird bio CEO over gene therapy licensebizjournals.com
- Gene therapy firm Bluebird Bio, with Durham site, to split into two companiesbizjournals.com
- News out of bluebird bio could delay IPOs for two local gene therapy firmsbizjournals.com